# Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

> **NCT06096337** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Boston Scientific Corporation** · enrollment: 484 (actual)

## Conditions studied

- Persistent Atrial Fibrillation

## Interventions

- **DEVICE:** FARAPULSE™ Pulsed Field Ablation (PFA) System
- **DRUG:** Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone

## Key facts

- **NCT ID:** NCT06096337
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-28
- **Primary completion:** 2026-02-04
- **Final completion:** 2028-02-04
- **Target enrollment:** 484 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06096337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06096337, "Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06096337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*